APRE
Aprea Therapeutics·NASDAQ
--
--(--)
--
--(--)
Latest data update time: Updated on 2026-01-31
Latest data update time: Updated on 2026-01-31
4.29 / 10Overall Score
NeturalInvestment Rating
4.29 / 10Overall Score
NeturalInvestment Rating
Is APRE a Good Buy Right Now?
- Based on a composite score of 4.29/10, we rate APRE as a Netural. Our analysis breaks down into 3.44/10 for Fundamentals, 3.41/10 for Technicals, and 5.14/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Technical Analysis of APRE?
Is APRE undervalued or overvalued?
Is money flowing into or out of APRE?
Is APRE a Good Buy Right Now?
- Based on a composite score of 4.29/10, we rate APRE as a Netural. Our analysis breaks down into 3.44/10 for Fundamentals, 3.41/10 for Technicals, and 5.14/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Is APRE undervalued or overvalued?
Technical Analysis of APRE?
Is money flowing into or out of APRE?
